Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It also offers paclitaxel polymer nanomicelles for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, gynecological tumors, etc. The company was founded in 2009 and is headquartered in Shanghai, China.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Zhou, Jingsong

Employees

375

Website

www.yizhongpharma.com

IPO Date

2021-09-09

Headquarters

No.79 Renqi Road, Fengxian District, Shanghai 201401, China

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

Shanghai Yizhong Pharmaceutical 688091

Shanghai Yizhong Pharmaceutical Earnings Call Summary

Shanghai Yizhong Pharmaceutical Earnings

Transcripts

Events

About Shanghai Yizhong Pharmaceutical Co., Ltd.

Shanghai Yizhong Pharmaceutical
688091